U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in...
Submission based on positive results of the landmark, global Phase 3 study, CheckMate -057 evaluating...
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC)...
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Tuesday, September 8 at 8 a.m....
coramaze technologies raises EUR 4.5 million to advance novel transfemoral mitral valve repair system...
Coramaze technologies GmbH, a German medical device company, is developing themitramaze® valve repair system –...
Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel...
"PRM-151 will complement our growing early-stage fibrosis portfolio, and we are excited by its potential...
Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel...
"We are excited to work with QIMR Berghofer Medical Research Institute, a partner that brings...
U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for...
This acceptance for review marks the first in the U.S. for a SLAMF7-directed immunostimulatory antibody...
Lilly To Participate In Morgan Stanley Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on...
Lilly, AACE Mark 10th Anniversary Of Hurricane Katrina With Reminder Of “My Diabetes Emergency...
The checklist, now in its ninth year, is a direct result of post-Katrina learnings...
U.S. District Court Rules In Lilly’s Favor On Alimta Vitamin Regimen Patent
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the...
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC...
Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating...
